2. Search Result
Search Result
Results for "

epileptic seizures

" in MedChemExpress (MCE) Product Catalog:

11

Inhibitors & Agonists

1

Peptides

3

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-W023493
    DL-Allylglycine

    2-Aminopent-4-enoic acid

    		 Amino Acid Derivatives Neurological Disease
    DL-Allylglycine (2-Aminopent-4-enoic acid) is a glutamate decarboxylase (GAD) inhibitor. DL-Allylglycine has convulsant activity that can be used in studies to induce epileptic seizures .
    DL-Allylglycine
  • HY-159819
    Vormatrigine

    		Sodium Channel Neurological Disease
    Vormatrigine is an orally active sodium channel inhibitor with anti-epileptic activity. Vormatrigine has a specific inhibitory effect on overactive NaV channels in vitro and has a good inhibitory effect in the maximal electroconvulsive seizure (MES) model. Vormatrigine can be used to study human focal and generalized epilepsy .
    Vormatrigine
  • HY-108234
    VU 0255035

    VU 255035

    		 mAChR Neurological Disease
    VU0255035 is a highly selective and competitive M1 mAChR antagonist. VU0255035 blocks M1 mAChR signals to reduce epileptic seizures and regulate neuronal membrane potential. VU0255035 can be used in research related to central nervous system diseases, such as epilepsy, Parkinson's disease, and dystonia .
    VU 0255035
  • HY-N2522
    Carboxyatractyloside dipotassium
    2 Publications Verification

    Gummiferin dipotassium

    		 Mitochondrial Metabolism Calcium Channel Reactive Oxygen Species (ROS) Neurological Disease
    Carboxyatractyloside dipotassium is a diterpenoid. Carboxyatractyloside dipotassium can be isolated from plants of the genus Xanthium. Carboxyatractyloside dipotassium is an ADP/ATP carrier inhibitor, inhibiting mitochondrial ADP/ATP transport. Carboxyatractyloside dipotassium promotes ROS production, induces Ca 2+ release, and leads to mitochondrial dysfunction. Carboxyatractyloside dipotassium induces lethargy, weakness, and epileptic seizures in rats .
    Carboxyatractyloside dipotassium
  • HY-N1502
    Carboxyatractyloside tripotassium
    2 Publications Verification

    Gummiferin tripotassium

    		 Mitochondrial Metabolism Reactive Oxygen Species (ROS) Calcium Channel Neurological Disease
    Carboxyatractyloside tripotassium is a diterpenoid. Carboxyatractyloside tripotassium can be isolated from plants of the genus Xanthium. Carboxyatractyloside tripotassium is an ADP/ATP carrier inhibitor, inhibiting mitochondrial ADP/ATP transport. Carboxyatractyloside tripotassium promotes ROS production, induces Ca 2+ release, and leads to mitochondrial dysfunction. Carboxyatractyloside tripotassium induces lethargy, weakness, and epileptic seizures in rats .
    Carboxyatractyloside tripotassium
  • HY-147423
    Zandatrigine
    1 Publications Verification

    NBI-921352; XEN901

    		 Sodium Channel Neurological Disease
    Zandatrigine (NBI-921352; XEN901) is a selective, orally active, voltage-gated sodium channel NaV1.6/SCN8A inhibitor that can penetrate the blood-brain barrier. Zandatrigine inhibits sodium influx by non-covalently binding to the VSD4 structure of NaV1.6, blocking the persistent and resuscitative currents under pathological conditions. Zandatrigine can reduce neuronal hyperexcitability and reduce epileptic seizures. Zandatrigine is 134-756-fold selective for other isoforms such as NaV1.1 and NaV1.2, and has minimal effect on NaV1.1 expressed by inhibitory interneurons. Zandatrigine can be used to study NaV1.6-mediated neuroexcitability diseases such as SCN8A-related developmental epileptic encephalopathy (SCN8A-DEE) and adult focal epilepsy .
    Zandatrigine
  • HY-130325
    α-Guanidinoglutaric acid

    		NO Synthase Neurological Disease
    α-Guanidinoglutaric acid is a guanidino compound first found in cobaltinduced epileptogenic focus tissue in the cerebral cortex of cats. α-Guanidinoglutaric acid induces epileptic seizures in rats after intraventricular administration .
    α-Guanidinoglutaric acid
  • HY-118931
    EF-1502

    		GABA Receptor Neurological Disease
    EF-1502 is a potent and selective GABA transporter inhibitor with GAT1 and BGT1 inhibitory activity. EF-1502 produces a synergistic anti-epileptic effect when used in combination with Tiagabine (HY-B0696), a compound used to suppress epileptic seizures. The dosing combination of EF-1502 exhibited reduced anti-epileptic efficacy and dyskinesia when used with THIP (HY-10232). The mechanism of EF-1502 differs significantly from Tiagabine, suggesting a unique role in the inhibitory strategy .
    EF-1502
  • HY-N2522R
    Carboxyatractyloside dipotassium (Standard)

    Gummiferin dipotassium (Standard)

    		 Reference Standards Mitochondrial Metabolism Calcium Channel Reactive Oxygen Species (ROS) Neurological Disease
    Carboxyatractyloside (dipotassium) (Standard) is the analytical standard of Carboxyatractyloside dipotassium (HY-N2522). This product is intended for research and analytical applications. Carboxyatractyloside dipotassium is a diterpenoid. Carboxyatractyloside dipotassium can be isolated from plants of the genus Xanthium. Carboxyatractyloside dipotassium is an ADP/ATP carrier inhibitor, inhibiting mitochondrial ADP/ATP transport. Carboxyatractyloside dipotassium promotes ROS production, induces Ca 2+ release, and leads to mitochondrial dysfunction. Carboxyatractyloside dipotassium induces lethargy, weakness, and epileptic seizures in rats .
    Carboxyatractyloside dipotassium (Standard)
  • HY-W818693
    3-Hydroxy-3-phenylpentanamide

    		Apoptosis Cancer
    3-Hydroxy-3-phenylpentanamide is a compound with neuroprotective activity. 3-Hydroxy-3-phenylpentanamide shows protective effects against ischemic brain injury and cerebral hemorrhage. 3-Hydroxy-3-phenylpentanamide is studied in psychiatry as a potential anxiety, depression and addiction suppressant compound. 3-Hydroxy-3-phenylpentanamide shows antitumor activity in oncology, acting by inducing apoptosis and inhibiting tumor growth. 3-Hydroxy-3-phenylpentanamide also has protective effects against epileptic seizures .
    3-Hydroxy-3-phenylpentanamide
  • HY-103181
    N6-Cyclopentyladenosine

    CPA; UK-80882

    		 Adenosine Receptor Apoptosis Cardiovascular Disease Neurological Disease Cancer
    N6-Cyclopentyladenosine (CPA) is a selective Adenosine A1 receptor agonist, with Ki values of 2.3 nM, 790 nM and 43 nM for human A1, A2A and A3 receptors, respectively. N6-cyclopentyladenosine increases Apoptosis. N6-Cyclopentyladenosine has antitumor activity against leukemia. N6-cyclopentyladenosine improves 5-fluorouracil (HY-90006)-induced hematopoietic damage, regulates sleep, and delays Aminophylline-induced clonic epileptic seizures .
    N6-Cyclopentyladenosine

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: